Jazz Pharmaceuticals plc

BRSE:J7Z Stock Report

Market Cap: CHF 6.8b

Jazz Pharmaceuticals Valuation

Is J7Z undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of J7Z when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
CHF 731.62
Fair Value
84.6% undervalued intrinsic discount
19
Number of Analysts

Below Fair Value: J7Z (CHF112.75) is trading below our estimate of fair value (CHF731.62)

Significantly Below Fair Value: J7Z is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for J7Z?

Key metric: As J7Z is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for J7Z. This is calculated by dividing J7Z's market cap by their current earnings.
What is J7Z's PE Ratio?
PE Ratio16.2x
EarningsUS$463.16m
Market CapUS$7.52b

Price to Earnings Ratio vs Peers

How does J7Z's PE Ratio compare to its peers?

The above table shows the PE ratio for J7Z vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average25.3x
DESN Dottikon ES Holding
40.1xn/aCHF 3.0b
COPN Cosmo Pharmaceuticals
16.1x21.5%CHF 1.1b
NOVN Novartis
17.4x6.7%CHF 188.8b
ROG Roche Holding
27.5x14.7%CHF 229.3b
J7Z Jazz Pharmaceuticals
16.2x12.2%CHF 7.5b

Price-To-Earnings vs Peers: J7Z is good value based on its Price-To-Earnings Ratio (16.2x) compared to the peer average (23.9x).

Price to Earnings Ratio vs Industry

How does J7Z's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
J7Z 16.2xIndustry Avg. 22.1xNo. of Companies10PE01632486480+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: J7Z is good value based on its Price-To-Earnings Ratio (16.2x) compared to the European Pharmaceuticals industry average (22x).

Price to Earnings Ratio vs Fair Ratio

What is J7Z's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

J7Z PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio16.2x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate J7Z's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst J7Z forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
CHF 164.79
0%
15.7%CHF 209.47CHF 116.57n/a19
Jan ’26CHF 112.57
CHF 161.91
+43.8%
15.8%CHF 205.68CHF 114.47n/a19
Dec ’25n/a
CHF 157.39
0%
16.4%CHF 203.91CHF 113.48n/a19
Nov ’25n/a
CHF 155.38
0%
16.5%CHF 199.22CHF 103.94n/a18
Oct ’25n/a
CHF 151.39
0%
16.8%CHF 194.76CHF 101.62n/a18
Sep ’25n/a
CHF 148.89
0%
18.1%CHF 194.98CHF 101.73n/a19
Aug ’25n/a
CHF 152.88
0%
18.2%CHF 200.93CHF 98.72n/a19
Jul ’25n/a
CHF 159.67
0%
16.2%CHF 204.98CHF 104.27n/a19
Jun ’25n/a
CHF 165.45
0%
16.7%CHF 210.37CHF 107.02n/a18
May ’25n/a
CHF 171.31
0%
15.6%CHF 209.36CHF 110.14n/a20
Apr ’25n/a
CHF 169.51
0%
14.9%CHF 206.55CHF 117.64n/a20
Mar ’25n/a
CHF 165.07
0%
15.6%CHF 203.15CHF 115.70n/a19
Feb ’25n/a
CHF 161.99
0%
16.0%CHF 202.43CHF 116.29n/a19
Jan ’25n/a
CHF 163.36
0%
15.8%CHF 205.33CHF 115.50CHF 112.5718
Dec ’24n/a
CHF 167.78
0%
14.6%CHF 208.64CHF 117.36n/a18
Nov ’24n/a
CHF 179.41
0%
11.9%CHF 216.38CHF 126.22n/a18
Oct ’24n/a
CHF 176.66
0%
12.0%CHF 211.74CHF 123.52n/a17
Sep ’24n/a
CHF 176.66
0%
12.0%CHF 211.74CHF 123.52n/a17
Aug ’24n/a
CHF 174.42
0%
11.6%CHF 208.75CHF 121.77n/a17
Jul ’24n/a
CHF 179.72
0%
12.0%CHF 215.94CHF 125.96n/a16
Jun ’24n/a
CHF 181.76
0%
9.3%CHF 217.38CHF 149.45n/a18
May ’24n/a
CHF 181.26
0%
8.0%CHF 215.65CHF 161.74n/a18
Apr ’24n/a
CHF 185.25
0%
7.6%CHF 219.80CHF 164.85n/a18
Mar ’24n/a
CHF 184.82
0%
7.9%CHF 221.09CHF 165.82n/a19
Feb ’24n/a
CHF 184.82
0%
7.9%CHF 221.09CHF 165.82n/a19
Analyst Price Target
Consensus Narrative from 19 Analysts
CHF 164.04
Fair Value
31.3% undervalued intrinsic discount
19
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/01 11:59
End of Day Share Price 2025/01/14 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Jazz Pharmaceuticals plc is covered by 51 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joel BeattyBaird
Ishan MajumdarBaptista Research
Richard SilverBarclays